CEP290 and Leber congenital amaurosis 10: For example, targeted genomic deletion using CRISPR-Cas9 represents a promising a therapeutic approach for the treatment of Leber Congenital Amaurosis 10 (LCA10), a severe retinal dystrophy, in patients with an intronic mutation in CEP290 [101].